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Abstract 
Background : To determine the zinc deficiency in 
patients with chronic hepatic encephalopathy  
 Methods: In this cross section study 
decompensated hepatic cirrhosis diagnosed patients 
(n=102) aged>16 years,both gender, with hepatic 
encephalopathy as per its grades were included. 
Blood samples were drawn and serum zinc levels 
were estimated.  
Results: Mean-age of patients was 51.5±9.5 years. 
Men (64.7%) constituted the  main. Zinc deficiency 
was noted in 68.6% patients. Hepatic encephalopathy 
grade II was most common  (42.2%) . Hepatic 
encephalopathy grading, II, III and IV were found 
significantly associated with zinc deficiency (p-
value= 0.007). No significant difference was found in 
zinc deficiency according to age p-value 0.739. Zinc 
deficiency was significantly higher among males (p-
value 0.043). 
Conclusion: Zinc deficiency was quite high 
(68.6%),with hepatic encephalopathy. Zinc 
deficiency was more common in males and middle 
age group patients.  
Key words: Liver cirrhosis, Zinc levels , 
Encephalopathy. 
Introduction 
Hepatic encephalopathy is a neuropsychiatric complex 
syndrome, correlated with hepatocellular dysfunction 
and elevated porto-systemic shunting, noticed within 
60% to 70% of hepatic cirrhosis patients.1,2 This 
reversible, complex, metabolic encephalopathy 
syndrome is a major complication of hepatic 
cirrhosis.3,4 Hepatic encephalopathy is distinguished 
via disruption within consciousness, instable 
neurological signs, personality and behavioral 
changes, asterixis and typical electroencephalographic 
variations. In severe cases irreversible coma and death 
can possibly as well take place. The two key 
mechanisms accountable for hepatic encephalopathy 
development are severe intrinsic liver failure or 
portosystemic shunts presence resulting in portal 
blood diversion towards systemic circulation earlier 
than removal of intestinal toxic substances.1,5 Zinc is 
vital trace constituent which as well functions as 
antioxidant.3 Low levels of zinc have been 
documented within patients with Hepatic 
encephalopathy and hepatic cirrhosis.3,6 It was 
observed in 69% of hepatic cirrhosis patients.7 A study 
reported that levels of blood ammonia are inversely 
correlated with levels of blood zinc in fasting. 8 Zinc 
accelerates the kinetics of formation of urea from 
amino acids and ammonia.9 In agreement deficiency of 
zinc in hepatic cirrhosis seems to be because of low 
absorption and high excretion of urine for which 
administration of excessive diuretics is accountable to some 
extent.7,1,8 It has been reported that Zinc improves the 
psychometric functioning in hepatic cirrhosis, very long-
term supplementations improve severe encephalopathy 
and thus quality of life.10,11Supplementation is important 
in prevention of hepatic encephalopathy by activating 
glutamine synthetase.8 Zinc supplements are also 
beneficial in urea cycle, protein, glucose metabolism, 
and neuro transmission11. Zinc supplementation in 
dose of 600 mg per day is recommended for 3 months 
period.1,4 Considering the clinical proof, that zinc 
deficiency may have a contribution in pathogenesis of 
Hepatic encephalopathy and patients improve from it 
by replacing the zinc. Though, association between 
blood levels and state of mind in cirrhosis is not 
accurate. The permeability of blood-brain barriers to 
ammonia is raised within Hepatic encephalopathy 
patients consequently, blood levels weakly associate 
with brain values, however recurrent studies exhibit 
progress of this association by the correction ammonia 
value to blood pH.12 Patients of chronic hepatic 
encephalopathy due to zinc deficiency is a critical 
condition resulting progressive worsening of 
encephalopathy and death, so careful observation and 
management are required.13  
 
Patients and Methods 
Following approval from hospital ethical committee, 
this study was carried out in Gastroenterology 
department of Isra University Hospital,  Hyderabad. 
Study duration was 6 months from January to June 
2011. All decompensated hepatic cirrhosis diagnosed 
patients aged >16 years, both gender, with hepatic 
Journal of Rawalpindi Medical College (JRMC); 2018;22(3): 248-251 
 
 249 
encephalopathy signs as per its grades were taken in 
study.All the patients with fulminant hepatic 
dysfunction, compensated hepatic disease, or without 
previous history of hepatic disorder were excluded, 
since, zinc deficiency was not noticed within patients 
of acute hepatic dysfunctions. Patients influenced by 
metabolic and neurological disorders like alcoholism, 
end  stage renal disease, and diabetes mellitus, history 
of trans-jugular intrahepatic portosystemic shunt, 
history of intake of drug as tranquillizers or subjects 
with fresh head trauma were not included in study so 
as to prevent coexistent neuropathy or further brain 
failure. Patients were considered as suffering from 
hepatic encephalopathy according to the four grades 
of encephalopathy.4  Grade 1 constituted euphoric or 
depression, disordered sleep, slurred speech, mild 
confusion, Asterixis   may be present or absent.Grade 
II constituted moderate confusion, lethargy, and 
Asterixis. Grade III constituted sleeping but arousable, 
incoherent speech, marked confusion, and 
asterixis.Grade IV constituted coma, at first responsive 
to noxious inducements, and unresponsive later. Blood 
samples drawn from all patients and were sent to 
diagnostic laboratory of Isra University Hospital, for 
zinc levels estimation 
 
Results 
Most common age group was 40 – 59 years 49 (48.0%), 
followed by 60–80 years with percentage of 31 (30.4%) 
and 22-39 years age group was found in 22 (21.6%) 
patients. The mean-age and standard deviation was 
51.5 ± 29.5 years. Men were more in number compared 
to females study participants as (64.7%) and (35.3%), 
respectively (Table 1). 
Table 1: Patients distribution according to age 
and gender (n=102) 
Variables Frequency (%) 
Age groups (years) 
22-39 22 (21.6%) 
40 - 59 49 (48.0%) 
60 - 80 31 (30.4%) 
Total 102(100.0%) 
Gender 
Male  66(64.7%) 
Female  46(35.3%) 
Total  102(100.0%) 
Mean ± SD= 51.5 ± 29.5 years 
 
Out of total 102 patients 70(68.6%) patients exhibited 
serum zinc deficiency compared to 32 (31.14%) non-
deficient cases. According to the grading of hepatic 
encephalopathy grade II was most common 42.2%, 
grade I was 25.5% and grade III was found in 20.6% of 
the cases, while grade IV was found only in 11.8% of 
the cases (Table 2).Grade  II, III and IV were found 
significantly associated with zinc deficiency (p-value 
0.007), while grade I was found significant in normal 
cases(Table 3).No significant difference was found in 
zinc deficiency according to age groups in patients 
with hepatic encephalopathy p-value 0.739. Male 
gender was found mostly associated with zinc 
deficiency, while mostly female were found with 
normal zinc level(p-value 0.043) (Table 3). 
 
Table 2: Zinc levels and grading of hepatic 
encephalopathy 
Variables  Frequency % 
Zinc level 
Normal  32 31.4% 
Deficient  70 68.6% 
Total  102 100.0% 
Hepatic encephalopathy 
Grade1 26 25.5% 
Grade 2 43 42.2% 
Grade 3 21 20.6% 
Grade 4 12 11.8% 
Total 102 100.0% 
 
Table 3: zinc deficiency according to HE 
grading, age and gender 
Variable
s  
Zinc level  
Total  
 
p-value  Deficiency Normal 
Hepaticencephalopathy  
 
 
0.007 
Grade I 10(14.9%) 16(45.7%) 26(25.5%) 
Grade II 31(46.3%) 12(34.3%) 43(42.2%) 
Grade 
III 
16(23.9%) 5(14.3%) 21(20.6%) 
Grade 
IV 
10(14.9%) 2(5.7%) 12(11.8%) 
Total 67(100.0%) 35(100.0%) 102(100.0%) 
Age groups  
 
 
0.739 
22-39 14(20.9%) 8(22.9%) 22(21.6%) 
40 - 59 34(50.7%) 15(42.9%) 49(48.0%) 
60 - 80 19(28.4%) 12(34.3%) 31(30.4%) 
Total  67(100.0%) 35(100.0%) 102(100.0%) 
Gender  
 
0.043 
Male  48(71.6%) 18(51.4%) 66(64.7%) 
Female  19(28.4%) 17(48.6%) 36(35.3%) 
Total  67(100.0%) 35(100.0%) 102(100.0%) 
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Discussion 
Development of the hepatic encephalopathy is 
explained, to some extent, with effect of neurotoxic 
substances, which may occurr in cases with cirrhosis 
and portal hypertension. Zinc is essential for 
coenzyme synthesis, which mediate biogenic amine 
synthesis and metabolism. In this study Zinc 
deficiency noted within 68.6% of the chronic HE 
patients  comparable to a similar study ,  by Soomro 
AA et al which noted zinc deficiency  69% of subjects 
among hepatic cirrhotic subjects.7 Low levels of zinc 
have been documented within subjects with HE  and 
hepatic cirrhosis.3,6 In another study of Waheed A et 
al13Zinc deficiency among patients with hepatic 
encephalopathy was 71.9%.  Inconsistently Kamani L  
et al  reported that overall prevalence of zinc 
deficiency is  28.9%, which is low according to our 
findings. This difference may because in their study 
only cirrhosis patients were selected with chronic 
hepatic encephalopathy.  14  Consistently Prasad CK et 
al reported that zinc deficiency among cirrhosis 
patients is 70%. 15 These findings were confirmed by 
Kugelmans’ study, who stated that lower level of  zinc 
with lower ingestion due to protein reluctance, 
increased loss in gastroenterological system due to 
diarrhea or intestinal malabsorption and increased 
urinary losses.16 
In our study the patients’ mean age was 51.5 ± 29.5 
years and males were most common (64.7%) as 
compared to females (35.3%). Similarly in the study of 
Waheed A et al13reported that patient’s mean age was 
47.8±7.5 years and 79(69.3%) patients were male while 
35(30.7%) patients were female.Soomro AA et al also 
found mean of patients as 42.75± 15.88 years, and 
males were 55.7% and females were 44.3%.7 According 
to the Siddique A et al mean age was 43.65+4.21 
years.17  Findings of these studies regarding mean age 
and gender distribution are consistent to this study.  
In this study HE  grade II was most common 42.2%, 
followed by grade I was 25.5% and grade III was 
20.6%, while grade IV was found only in 11.8% cases. 
While Waheed A et al grade III was most common as 
47 (41.2%), 18(15.8%) patients were with  grade-I, 
32(28.1%) presented with grade-II, and 17 (14.9%) 
patients had grade-IV. 13 In our research middle aged 
males were in majority compared to women and 
deficiency of zinc was noted frequently in men like 
majority of other researches. Supplementation of zinc 
besides rifaximin, a modestly absorbed antibiotic, can 
possibly be further effective within refractory HE, 
because a fresh research exhibited the dominance of 
rifaximin over lactulose only treatment in severe 
recurrent HE  subjects. 
In this study, most subjects were from periphery / 
interior of Sindh province and this can possibly be due 
to improper counseling, motivational deficiency, lack 
of awareness and poor hygiene. Present study  
established that most patients were aged >40 years, 
though a study held in Balouchistan, Pakistanon 
spectrum of CLD, as well had similar 
findings.18Deficiency of zinc is frequent among 
cirrhotic subjects, specifically with alcohol-induced 
hepatic injury. Supplementation of zinc has been 
exhibited to lower the levels of serum ammonia and 
fluctuating neurotransmitters such as γ-aminobutyric 
acid  and  norepinephrine within brain. Just small 
studies have been carried out by supplementation of 
zinc with equivocal outcomes. Zinc, oral agent, is 
accessible over-the-counter and contributes for zinc 
deficient patients. Zinc is accessible in many forms 
besides zinc acetate, zinc sulfate, and zinc 
gluconate.19,20Many reports state  that supplementation 
of zinc improve psychometric functioning with a 
decline in the level of blood ammonia within Hepatic 
encephalopathy subjects. Additionally, combinations 
of conventional therapies and zinc for example a 
protein-limited diet including lactitol or BCAA 
preparation have been stated as successful therapies 
for Hepatic encephalopathy. 
According to this study supplementation of zinc 
besides standard treatment evidently exhibited 
improved hepatic functions, Hepatic Encephalopathy, 
Neuropsychiatric tests, and  Health Related Quality Of 
Life especially Physical Component Status, in 
decompensated hepatic cirrhosis patients. Several 
reports report that supplementation of zinc improve 
psychometric functioning with a drop of level in blood 
ammonia among hepatic encephalopathy patients.21,22 
Furthermore, combination of conventional therapies & 
zinc for instance a protein limited diet together with 
lactitol or BCAA preparation have been documented 
as successful therapies for Hepatic encephalopathy. 
Hayashi et al.23 documented that combination 
treatments with zinc supplements and  BCAA 
diminish level of blood ammonia further than BCAA 
treatment only in cirrhotic subjects in the course of 
study period. They concluded from this finding that 
administration of zinc raised the hepatic ability for 
metabolizing ammonia contrasted to the nitrogen load 
via supplementation of BCAA. Katayama et 
al24documented that while either zinc or lactitol alone 
diminished levels of ammonia to around 70% of pre-
treatment concentrations, combination treatment  
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lowered them to around 50%. Synthetic disaccharides 
effectively reduce blood ammonia via primarily 
preventing intestinal absorption of ammonia, and are 
believed to enhance NP tests.25,26 This two agents’ 
synergism to reduce ammonia resulting from various 
mechanisms appears to be useful in subjects who are 
non-responsive to standard treatments only. 
Supplementation of zinc besides Rifaximin, a 
moderately absorbed antibiotic, can possibly be 
further successful in refractory Hepatic 
encephalopathy, because a fresh research, exhibited 
the dominance of Rifaximin treatment over lactulose 
only treatment in severe recurring Hepatic 
encephalopathy subjects. 27   
 
Conclusion 
1. Low levels of serum Zinc are frequent (68%) and it 
has higher effect on incidence of hepatic 
encephalopathy. A definite requisite for proper 
counseling and health education is needed of 
subjects diagnosed as hepatic cirrhosis regarding 
hepatic encephalopathy.  
2. It is required to identify markers of exposure to 
deficiency of zinc in addition to effective 
approaches to diminish zinc deficiency as well as 
its consequences. 
3. It is required to assess rule of zinc therapy in 
hepatic encephalopathy patients  
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